ERS Genomics Ltd.. (10/16/18). "Press Release: ERS Genomics and Syngulon Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Industrial Applications". Dublin & Seraing.

	Organisation	ERS Genomics Ltd.
	Organisation 2	Syngulon S.A.
	Product	CRISPR gene editing technology
	Product 2	synthetic biotechnology
	Person	Rhodes, Eric (ERS Genomics 201606– CEO before Horizon Discovery since 201201 before Sigma-Aldrich + Sangamo Biosciences)

ERS Genomics Limited and Syngulon, a synthetic biology startup developing original genetic technologies using bacteriocins, announced today a non-exclusive license agreement which provides Syngulon with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in combination with Syngulon Patent Rights. ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.

“Genome editing has many applications beyond drug discovery and development and making the CRISPR-Cas9 patents available to synthetic biology startups such as Syngulon is a growing and important part of our business. We are thus very pleased to include them in our expanding portfolio of licensees,” said Eric Rhodes, CEO of ERS Genomics.

“By combining modern genetics with synthetic biology, Syngulon is developing its collection of bacteriocins a.k.a. anti-microbial peptides to fight contaminants in different industrial applications. Syngulon outlicenses its patented technologies on a non-exclusive basis and will be able to sublicense ERS’ CRISPR-Cas9 patents as part of a Joint Licensing agreement thus enabling its licensees to benefit from the use of CRISPR-Cas9 genome editing in implementing Syngulon’s technologies using bacteriocins,” commented Dr Philippe Gabant, Co-founder & CSO of Syngulon.

Dr. Emmanuelle Charpentier’s research unveiled the key components and mechanisms of the CRISPR-Cas9 system, leading to the landmark publication with Jennifer Doudna, (Jinek et al., 2012), which laid the foundation for the use of CRISPR-Cas9 as a highly versatile and precise genome editing tool.

Financial details of the agreement were not disclosed.

ERS Genomics was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology: www.ersgenomics.com.

Contact ERS Genomics:

MacDougall Biomedical Communications
Mario Brkulj or Kara Mazey
Direct: +49 89 2420 9345 or +1 781 235 3060
E-Mail: ersgenomics@macbiocom.com

Record changed: 2023-06-05

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for ERS Genomics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)